Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	141.79	118.32	151.89
Short-Term Investments	378.86	277.14	-
Cash & Short-Term Investments	520.65	395.46	151.89
Cash Growth	31.66%	160.36%	-
Other Receivables	4.7	1.21	-
Receivables	4.7	1.21	-
Prepaid Expenses	2.62	1.74	0.11
Other Current Assets	1.74	-	0.06
Total Current Assets	529.71	398.41	152.06
Property, Plant & Equipment	13.32	2.59	-
Long-Term Investments	210.42	-	-
Other Long-Term Assets	0.5	0.4	-
Total Assets	753.95	401.4	152.06
Accounts Payable	1.07	2.14	0.42
Accrued Expenses	24.26	17.31	9.56
Current Portion of Leases	3.23	1.1	-
Total Current Liabilities	28.56	20.56	9.98
Long-Term Leases	8.6	0.93	-
Total Liabilities	37.16	21.49	9.98
Common Stock	0	-	2.25
Additional Paid-In Capital	1,022	503.35	-
Retained Earnings	-305.92	-123.77	-39.79
Comprehensive Income & Other	0.92	0.33	2.14
Total Common Equity	716.79	379.91	-35.39
Shareholders' Equity	716.79	379.91	142.08
Total Liabilities & Equity	753.95	401.4	152.06
Total Debt	11.83	2.03	-
Net Cash (Debt)	719.24	393.43	151.89
Net Cash Growth	82.82%	159.02%	-
Net Cash Per Share	13.03	15.73	61.69
Filing Date Shares Outstanding	58.09	48.52	5
Total Common Shares Outstanding	58.06	48.52	5
Working Capital	501.15	377.85	142.08
Book Value Per Share	12.35	7.83	-7.08
Tangible Book Value	716.79	379.91	-35.39
Tangible Book Value Per Share	12.35	7.83	-7.08
Machinery	1.29	-	-
Leasehold Improvements	0.86	-	-

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q